1,6-Dihydro-6-oxo-5-pyridazinedicarbonitrile | 343864-91-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1,6-Dihydro-6-oxo-5-pyridazinedicarbonitrile
• 英文别名: 6-oxo-1H-pyridazine-4,5-dicarbonitrile
• CAS: 343864-91-5
• 化学式: C₆H₂N₄O
• 分子量: 146.11
• InChiKey: VCLUOFBFTWUWIJ-UHFFFAOYSA-N

物化性质

• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  89
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1,6-Dihydro-6-oxo-5-pyridazinedicarbonitrile 生成 4,5-二氨基-3-羟基吡嗪
  参考文献：
  名称：

  CHEN C.-F.; PANZICA R. P., J. HETEROCYCL. CHEM., 1981, 18, NO 2, 303-307

  摘要：

  DOI：
• 作为产物：
  描述：

  4,5-二氯-3-羟基哒嗪 、 氰化钾 生成 1,6-Dihydro-6-oxo-5-pyridazinedicarbonitrile
  参考文献：
  名称：

  CHEN C.-F.; PANZICA R. P., J. HETEROCYCL. CHEM., 1981, 18, NO 2, 303-307

  摘要：

  DOI：

文献信息

• Phosphodiesterase type III (PDE III) inhibitors or CA2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
  申请人：Boehringer Ingelheim Vetmedica GmbH

  公开号：EP2702986A1

  公开（公告）日：2014-03-05

  The present invention relates to a phosphodiesterase type III (PDE III) inhibitor and/or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the treatment of a patient suffering from hypertrophic cardiomyopathy (HCM). According to another aspect the present invention relates to the use of a PDE III inhibitor and/or Ca2+-sensitizing agent for the preparation of a medicament for the treatment of a patient suffering from HCM.

  本发明涉及一种磷酸二酯酶 III 型 (PDE III) 抑制剂和/或 Ca2+ 增敏剂或其药学上可接受的衍生物，用于治疗肥厚型心肌病 (HCM) 患者。根据另一个方面，本发明涉及使用 PDE III 抑制剂和/或 Ca2+ 增敏剂制备治疗 HCM 患者的药物。
• Phosphodiesterase type III (PDE III) inhibitors or Ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
  申请人：Boehringer Ingelheim Vetmedica GmbH

  公开号：EP2702987A1

  公开（公告）日：2014-03-05

  The present invention relates to a phosphodiesterase type III (PDE III) inhibitor and/or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the treatment of a patient suffering from hypertrophic cardiomyopathy (HCM). According to another aspect the present invention relates to the use of a PDE III inhibitor and/or Ca2+-sensitizing agent for the preparation of a medicament for the treatment of a patient suffering from HCM.

  本发明涉及一种磷酸二酯酶 III 型 (PDE III) 抑制剂和/或 Ca2+ 增敏剂或其药学上可接受的衍生物，用于治疗肥厚型心肌病 (HCM) 患者。根据另一个方面，本发明涉及使用 PDE III 抑制剂和/或 Ca2+ 增敏剂制备治疗 HCM 患者的药物。
• USE OF PDE III INHIBITORS FOR THE TREAMENT OF ASYMPTOMATIC (OCCULT) HEART FAILURE
  申请人：Boehringer Ingelheim Vetmedica GmbH

  公开号：EP3210605A1

  公开（公告）日：2017-08-30

  The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor and/or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patients having an asymptomatic (occult) heart failure and/or for the reduction of heart size in patients having an asymptomatic (occult) heart failure.

  本发明涉及一种磷酸二酯酶 III 型 (PDE III) 抑制剂和/或 Ca2+ 增敏剂或其药学上可接受的衍生物，用于制备延长无症状（隐匿性）心力衰竭患者出现临床症状前的时间和/或缩小无症状（隐匿性）心力衰竭患者心脏体积的药物。
• PDE III inhibitors for treatment of asymptomatic heart failure
  申请人：Daemmgen Juergen

  公开号：US10117869B2

  公开（公告）日：2018-11-06

  Phosphodiesterase type III (PDE III) inhibitor or a “Ca2+-sensitizing agent” or a pharmaceutically acceptable derivative thereof is used in the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure, and as a medication for the reverse remodeling of the heart of a patient with asymptomatic (occult) heart failure and their delayed onset of clinical symptoms.

  磷酸二酯酶 III 型（PDE III）抑制剂或 "Ca2+敏化剂 "或其药学上可接受的衍生物可用于制备缩小心力衰竭患者心脏体积的药物，以及用于逆转无症状（隐匿性）心力衰竭患者的心脏重塑和延迟出现临床症状的药物。
• Use of pimobendan for the reduction of heart size in mammals suffering from heart failure
  申请人：Boehringer Ingelheim Vetmedica GmbH

  公开号：US10537588B2

  公开（公告）日：2020-01-21

  A phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.

  本发明提供了一种磷酸二酯酶 III 型（PDE III）抑制剂或 Ca2+ 增敏剂或其药学上可接受的衍生物，用于制备缩小心力衰竭患者心脏体积的药物。